meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
atezolizumab plus SoC
title
placebo plus SoC
title
IMspire-150 (BRAF mutant), 2020 NCT02908672 mML - L1 - BRAF mutant 256/258
Pathology:
mML - L1 - BRAF mutant;
mML - L1 - BRAF mutant
IMspire-150 (BRAF mutant), 2020
atezolizumab plus SoC
1
T1
placebo plus SoC
0
T0